Gastric cancer is a malignant tumor that starts in the lining of the stomach. When detected early and treated promptly, most patients can achieve long-term survival or even clinical cure.
Globally, nearly 970,000 new cases are reported annually, making it the fifth most common cancer.
China accounts for nearly half of the world's gastric cancer cases—approximately 480,000 new patients each year. At Fosun Health, this extraordinary case volume has built unmatched expertise in what matters most to patients: preserving the stomach and the ability to eat normally after treatment. Our teams perform thousands of radical gastrectomies, function-preserving gastrectomies, and complex interventions annually. "The more we treat, the more precisely we protect your stomach—and your life."
Every gastric cancer program has surgery, drugs, and radiation. Here is what makes ours different:
"Can you remove the cancer while keeping as much of my stomach as possible—and protect my ability to eat?"
The challenge: For gastric cancer patients, the most haunting question is not simply survival—it is "Will I ever eat normally again?" Total gastrectomy means no stomach at all: tiny meals, lifelong nutritional supplements, dumping syndrome, and iron/B12 deficiency anemia. Even partial gastrectomy can leave you with a dysfunctional gastric remnant, severe reflux, or postoperative gastric paralysis.
Our answer: We do not default to "remove the whole stomach." Our approach is stomach-preserving by design:
- Early-stage / High-grade dysplasia: ESD/EMR endoscopic submucosal dissection removes the lesion through the endoscope—no abdominal incision, no removal of the stomach itself. Cure with the stomach fully intact.
- Proximal gastric tumors: Proximal gastrectomy with double-tract or double-muscular-flap anti-reflux reconstruction—removing only the upper diseased segment while preserving the distal stomach and pylorus. You keep a functioning reservoir, not a passive tube.
- Mid/distal early tumors: Pylorus-preserving gastrectomy (PPG) removes the cancer while keeping the pyloric valve intact—dramatically reducing dumping syndrome and bile reflux, preserving normal gastric emptying.
- Advanced tumors requiring total gastrectomy: Robotic-assisted D2/D2+ lymphadenectomy ensures radical clearance while meticulously preserving the vagus nerve branches that govern remnant bowel motility—reducing postoperative gastric paralysis and accelerating return to oral nutrition.
What this means for you: "Radical" does not have to mean "total." Wherever oncologically safe, we preserve every possible centimeter of functional stomach—so you eat real food, not just survive on supplements.
"My tumor is bleeding, blocking my stomach outlet, or causing terrible jaundice and belly swelling. I am too weak for major surgery. Can you save me first?"
The challenge: Advanced gastric cancer often brings terrifying complications: torrential bleeding from ulcerated tumors, pyloric or gastric outlet obstruction making eating impossible, bile duct compression causing jaundice, or malignant ascites distending the abdomen. Patients are malnourished, anemic, and frail—far too weak for major surgery. Without rapid intervention, the downward spiral accelerates.
Our answer: A minimally invasive interventional emergency platform that stabilizes you first—without opening the abdomen:
- Superselective gastric arterial embolization: Through a tiny groin puncture, a microcatheter navigates to the left gastric, right gastric, or gastroepiploic arteries feeding the tumor. Embolic agents permanently seal the bleeding vessel. Hemorrhage stops immediately. No abdominal incision. No general anesthesia.
- Gastrointestinal stenting: For pyloric, antral, or duodenal obstruction, a self-expanding metal stent (SEMS) is deployed endoscopically or under X-ray guidance—reopening the gastric outlet within hours, restoring the ability to eat and drink.
- Biliary drainage & stenting: For obstructive jaundice from pancreatic head or hilar metastases, PTCD percutaneous drainage or biliary stent placement relieves bile backup, protects liver function, and restores your strength for subsequent anticancer therapy.
- Ascites management: For malignant ascites causing respiratory distress and pain, percutaneous catheter drainage combined with intraperitoneal therapy rapidly relieves pressure and discomfort.
- Conversion infusion: For locally advanced but non-metastatic tumors, superselective arterial infusion chemotherapy (drug concentrations 50–100× IV levels) shrinks the tumor—converting an emergency obstruction into a planned elective surgery with curative intent.
What this means for you: When bleeding, blockage, or jaundice strikes, you do not need to be strong enough for major surgery. Our interventional team can stop the bleeding, reopen your digestive channel, drain the pressure, and shrink the tumor—often in a single session—giving you the stability to proceed with definitive treatment.
"I have already had gastric surgery. Now the cancer has returned at the connection site, or in lymph nodes near my stomach. Do I need another major open operation?"
The challenge: Postoperative recurrence at the gastric bed, anastomosis, or regional/retroperitoneal lymph nodes is devastating. Re-operative surgery in the upper abdomen is fraught with dense adhesions, distorted anatomy, and high morbidity. Many patients are told "nothing more can be done surgically."
Our answer: CyberKnife M6 delivers 0.1mm sub-millimeter stereotactic radiosurgery. It tracks the tumor's motion with breathing and converges radiation from thousands of angles—precisely ablating:
- Postoperative local recurrences at the anastomosis or gastric bed
- Regional lymph node relapses
- Liver or lung oligometastases
Because it is completely non-invasive, there is no surgical trauma, no adhesion formation, no bleeding, and no interruption to your ongoing systemic therapy. The beam maximally spares the remaining stomach, duodenum, spinal cord, kidneys, and healthy bowel.
- Local recurrence: 1–5 outpatient sessions deliver curative-intent ablation.
- Oligometastases: Bone or lung spots eliminated without a single incision.
What this means for you: A scan showing recurrence does not automatically mean another major operation. CyberKnife eliminates isolated recurrence sites while you remain on your chemotherapy or targeted therapy—uninterrupted.
"I am HER2-positive and have progressed on trastuzumab. What is CLDN18.2? Can I afford these new drugs?"
The challenge: Gastric cancer treatment now depends heavily on molecular subtyping. HER2-positive tumors eventually resist trastuzumab. CLDN18.2—a target highly prevalent in Asian gastric cancers—requires newer agents. When standard first-line chemotherapy fails, the availability and cost of next-line targeted and immunotherapy agents determine whether you can keep fighting.
Our answer: In China, the molecular-matched next line comes sooner—and costs significantly less:
- HER2-positive disease: Trastuzumab deruxtecan (T-DXd)—a next-generation antibody-drug conjugate with unprecedented response rates in previously treated HER2-positive and HER2-low gastric cancer. Also HER2-directed bispecific antibodies for resistant cases.
- CLDN18.2-positive disease: Zolbetuximab-based targeted therapy—a first-in-class agent for this Asian-prevalent target, available in China.
- Advanced/metastatic disease: China-original combination protocols such as camrelizumab (anti-PD-1) plus apatinib (VEGFR-2 inhibitor) combined with chemotherapy have demonstrated superior survival and are endorsed by CSCO guidelines.
- MSI-H / dMMR: PD-1 immunotherapy offers deep, durable remissions.
Because these therapies are developed and manufactured within China's integrated ecosystem, comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality. Guided by NGS profiling and physicians who have sequenced thousands of gastric cancer cases through multiple lines.
What this means for you: Your tumor's HER2, CLDN18.2, MSI, or PD-L1 status is not just a label—it is a direct map to drugs that are available here, now, at a sustainable cost.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as a "gastric function guardian":
Toxicity Reduction: Herbal formulations protect gastric mucosa, regulate digestive enzymes, ease chemotherapy-induced nausea and vomiting, reduce anorexia and fatigue, and prevent postoperative or post-radiation esophageal/jejunal stricture.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to chemotherapy or targeted agents.
Acupuncture provides additional support for post-gastrectomy gastroparesis, nausea, reflux, and cancer-related fatigue. The goal: protect residual digestive function, reduce treatment burden, and keep you strong enough to complete every planned cycle—on schedule.
Every gastric cancer case is reviewed by a panel comprising gastric surgery, hepatobiliary surgery (for biliary involvement), interventional radiology, medical oncology, radiation oncology, gastroenterology/endoscopy, radiology, and pathology specialists. Gastric cancer decisions are uniquely complex: endoscopic resection versus laparoscopic surgery versus open radical resection; total versus proximal versus pylorus-preserving gastrectomy; neoadjuvant chemotherapy versus upfront surgery; and sequencing of targeted/immunotherapy through lines of resistance.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your cancer stage, molecular profile, nutritional status, and your priorities.
Diagnosis:
Stage III Gastric Cancer
Treatment Plan:
Neoadjuvant CyberKnife radiotherapy followed by surgical resection and adjuvant chemotherapy. In addition, an immunomodulatory agent available in China was administered to enhance immune function and further reduce the long-term risk of recurrence.
Outcome:
At the 18-month follow-up, computed tomography (CT) and endoscopic examinations showed no evidence of disease recurrence. The patient had no limitations in daily activities, remained fully independent in self-care, and achieved clinical remission.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your complete medical documentation: gastroscopy reports with pathology, endoscopic ultrasound (EUS) images, contrast-enhanced CT scans of chest-abdomen-pelvis, PET-CT reports, and NGS/genetic sequencing results (HER2, CLDN18.2, MSI/dMMR, EBV). The Fosun Health Gastric Cancer MDT Panel will conduct a comprehensive evaluation and deliver a personalized preliminary treatment plan—including function-preservation feasibility and interventional downstaging strategy—within 48 hours.
